文献速递前列腺增生与排尿功能障碍

长期使用A型肉毒毒素治疗可对膀胱过度活动症患者的健康相关生活质量产生一致且持久的改善

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
PubMed 文献 · J Urol · 2017-05-20

本研究报告了重复使用A型肉毒毒素100 U治疗对膀胱过度活动症伴尿失禁患者的长期健康相关生活质量影响。患者完成两项24周III期试验之一后可进入3年扩展研究并按需多次治疗。结果显示I-QOL和KHQ评分改善持续为最小重要差异的2至6倍,首次治疗有效者后续多持续有效,首次无效者中38.3%后续可达有效改善。

要点

  • 重复A型肉毒毒素100 U治疗6次内I-QOL改善持续为最小重要差异的2至3倍
  • KHQ角色受限和社会受限领域改善分别为最小重要差异的5至6倍和3至4倍
  • 首次治疗达最小重要差异者中72.9%后续所有治疗均达标,首次无效者中38.3%后续可改善

核心结论

  • 在膀胱过度活动症伴尿失禁患者中,重复A型肉毒毒素100 U治疗可观察到一致且具有临床意义的健康相关生活质量改善。
  • 首次治疗有积极反应倾向于预测后续治疗有类似反应,而首次治疗无反应并不排除后续治疗出现积极反应。

研究设计与样本

  • 完成两项24周III期试验之一患者可进入3年扩展研究,并按需请求多次A型肉毒毒素100 U治疗。
  • 报告I-QOL和KHQ结果,最多涵盖6次治疗。
  • 通过按首次治疗I-QOL反应分类患者并分析第2至6次治疗反应,评估重复治疗反应的一致性。

主要发现

  • 第1至6次A型肉毒毒素治疗后,I-QOL评分改善持续为最小重要差异的2至3倍。
  • KHQ角色受限领域评分改善为最小重要差异的5至6倍,社会受限领域评分改善为最小重要差异的3至4倍。
  • 多数患者达到或超过I-QOL和KHQ领域评分的最小重要差异。
  • 首次治疗达到或超过I-QOL最小重要差异者中,72.9%在所有后续治疗中均达到或超过该差异。
  • 首次治疗后反应不佳者中,38.3%在所有后续治疗中改善超过最小重要差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present the long-term effects of repeat onabotulinumtoxinA 100 U treatment on health related quality of life in patients with overactive bladder and urinary incontinence who had an inadequate response to and/or were intolerant of an anticholinergic. MATERIALS AND METHODS: Patients who completed either of 2, 24-week phase III trials could enter a 3-year extension study and request multiple onabotulinumtoxinA 100 U treatments as needed. Results of the I-QOL (Incontinence-Quality of Life) and KHQ (King's Health Questionnaire) are reported for up to 6 treatments. Consistency of the response to repeat onabotulinumtoxinA treatments was evaluated by classifying patients by the I-QOL response to the first treatment and analyzing responses to treatments 2 to 6. RESULTS: After onabotulinumtoxinA treatments 1 to 6, improvements in I-QOL scores were consistently 2 to 3 times the minimally important difference, and improvements in KHQ role limitations and social limitations domain scores were 5 to 6 and 3 to 4 times the minimally important difference, respectively. Most patients achieved or exceeded the minimally important difference for I-QOL and KHQ domain scores. Furthermore, 72.9% of patients who achieved or exceeded the minimally important difference for I-QOL after treatment 1 did so for all subsequent treatments. Of patients with a poor response after treatment 1, 38.3% achieved improvements greater than the minimally important difference for all subsequent treatments. CONCLUSIONS: In patients with overactive bladder and incontinence consistent and clinically meaningful improvements in health related quality of life were observed with repeat onabotulinumtoxinA 100 U treatments. A positive response after treatment 1 tended to predict similar responses to subsequent treatments, whereas a lack of response to treatment 1 did not preclude positive response(s) to later treatments.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ginsberg DA, Drake MJ, Kaufmann A, et al. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder. J Urol. 2017. PMID: 28536084. doi:10.1016/j.juro.2017.05.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。